HK1207796A1 - Glufosfamide combination therapies for cancer - Google Patents
Glufosfamide combination therapies for cancerInfo
- Publication number
- HK1207796A1 HK1207796A1 HK15108524.1A HK15108524A HK1207796A1 HK 1207796 A1 HK1207796 A1 HK 1207796A1 HK 15108524 A HK15108524 A HK 15108524A HK 1207796 A1 HK1207796 A1 HK 1207796A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- cancer
- combination therapies
- glufosfamide
- glufosfamide combination
- therapies
- Prior art date
Links
- PSVUJBVBCOISSP-SPFKKGSWSA-N (2s,3r,4s,5s,6r)-2-bis(2-chloroethylamino)phosphoryloxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound OC[C@H]1O[C@@H](OP(=O)(NCCCl)NCCCl)[C@H](O)[C@@H](O)[C@@H]1O PSVUJBVBCOISSP-SPFKKGSWSA-N 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 238000002648 combination therapy Methods 0.000 title 1
- 229950011595 glufosfamide Drugs 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7024—Esters of saccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261687114P | 2012-04-19 | 2012-04-19 | |
PCT/US2012/053275 WO2013158143A1 (fr) | 2012-04-19 | 2012-08-31 | Polythérapies par glufosfamide pour le cancer |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1207796A1 true HK1207796A1 (en) | 2016-02-12 |
Family
ID=49380659
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK15108524.1A HK1207796A1 (en) | 2012-04-19 | 2015-09-01 | Glufosfamide combination therapies for cancer |
Country Status (7)
Country | Link |
---|---|
US (1) | US20130281386A1 (fr) |
EP (1) | EP2846638A4 (fr) |
JP (3) | JP2015514756A (fr) |
CN (1) | CN104270944A (fr) |
CA (1) | CA2870138A1 (fr) |
HK (1) | HK1207796A1 (fr) |
WO (1) | WO2013158143A1 (fr) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2016134486A1 (fr) * | 2015-02-27 | 2016-09-01 | Steinberg Gregory | Utilisation de canagliflozine et de ses dérivés dans le traitement du cancer |
CN105030798B (zh) * | 2015-06-24 | 2017-11-24 | 李宏 | 一种抗肿瘤的药物组合物及其制备方法和应用 |
EP3490543A4 (fr) * | 2016-08-01 | 2020-04-01 | IC-Medtech Corp. | Acide ascorbique, composé de quinone et inhibiteur de co-transporteur de glucose de sodium pour le traitement du cancer. |
WO2019105149A1 (fr) * | 2017-11-28 | 2019-06-06 | 深圳艾欣达伟医药科技有限公司 | Utilisation médicale de glufosfamide contre le cancer |
JP7414230B2 (ja) * | 2018-11-09 | 2024-01-16 | 国立大学法人 琉球大学 | 抗血液悪性腫瘍薬 |
WO2020170240A1 (fr) | 2019-02-21 | 2020-08-27 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Procédé de réduction d'une néphrotoxicité induite par des médicaments |
CN110038009B (zh) | 2019-05-13 | 2021-01-08 | 浙江大学 | 卡格列净在制备抗肿瘤药物中的应用 |
KR102437311B1 (ko) * | 2019-12-03 | 2022-09-15 | 주식회사 하임네이처 | Ndpk 활성제 및 sglt-2 억제제를 포함하는 암의 예방 또는 치료용 약학 조성물 |
KR20210084919A (ko) * | 2019-12-30 | 2021-07-08 | 주식회사 하임바이오 | Sglt-2 억제제 및 고시폴을 유효성분으로 포함하는 암의 예방 또는 치료용 약학 조성물 |
IL300847A (en) * | 2020-08-26 | 2023-04-01 | Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd | Combined treatment to reduce DRUG-INDUCED NEPHROTOXICITY, DYSLIPIDEMIA AND HYPERGLYCEMIA |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA1289077C (fr) * | 1984-08-13 | 1991-09-17 | Harry H. Leveen | Traitement du cancer a l'aide de la phlorizine et de ses derives |
DE19806803A1 (de) * | 1998-02-18 | 1999-11-25 | Hermann Koepsell | Transporter für Saccharid-gekoppelte Zytostatika in Tumorzellen |
AU2003230750A1 (en) * | 2002-03-29 | 2003-10-13 | Threshold Pharmaceuticals, Inc. | Compositions and methods for treating cancer |
KR20050111752A (ko) * | 2003-03-07 | 2005-11-28 | 쓰레솔드 파마슈티컬스, 인코포레이티드 | 항신생물제에 의한 치료에 대한 종양의 감수성을 결정하는방법 |
WO2006122227A1 (fr) * | 2005-05-11 | 2006-11-16 | Threshold Pharmaceuticals, Inc. | Traitement par une association de glufosfamide |
US8765690B2 (en) * | 2007-04-05 | 2014-07-01 | Threshold Pharmaceuticals, Inc. | Treatment of cancer with glufosfamide in patients not receiving insulin therapy |
US8450286B2 (en) * | 2008-03-18 | 2013-05-28 | Bristol-Myers Squibb Company | Method for treating cancers having high glucose requirements employing an SGLT2 inhibitor and compositions thereof |
-
2012
- 2012-08-30 US US13/599,684 patent/US20130281386A1/en not_active Abandoned
- 2012-08-31 WO PCT/US2012/053275 patent/WO2013158143A1/fr active Application Filing
- 2012-08-31 JP JP2015506952A patent/JP2015514756A/ja not_active Withdrawn
- 2012-08-31 CA CA2870138A patent/CA2870138A1/fr not_active Abandoned
- 2012-08-31 CN CN201280072538.2A patent/CN104270944A/zh active Pending
- 2012-08-31 EP EP12874672.4A patent/EP2846638A4/fr not_active Withdrawn
-
2015
- 2015-09-01 HK HK15108524.1A patent/HK1207796A1/xx unknown
-
2018
- 2018-02-16 JP JP2018025930A patent/JP2018087228A/ja not_active Withdrawn
-
2020
- 2020-01-17 JP JP2020005694A patent/JP2020055884A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
EP2846638A4 (fr) | 2016-03-02 |
WO2013158143A1 (fr) | 2013-10-24 |
CN104270944A (zh) | 2015-01-07 |
JP2015514756A (ja) | 2015-05-21 |
CA2870138A1 (fr) | 2013-10-24 |
US20130281386A1 (en) | 2013-10-24 |
JP2018087228A (ja) | 2018-06-07 |
EP2846638A1 (fr) | 2015-03-18 |
JP2020055884A (ja) | 2020-04-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1223552A1 (zh) | 用於癌症的組合療法 | |
IL254716B (en) | Zinc-lysine conjugate | |
HK1211475A1 (en) | Combination therapy | |
EP2934531A4 (fr) | Combinaison | |
GB201208309D0 (en) | Complexes | |
HK1207796A1 (en) | Glufosfamide combination therapies for cancer | |
EP2853789A4 (fr) | Partie coulissante | |
EP2935741A4 (fr) | Mécanisme de verrou | |
EP2896853A4 (fr) | Partie coulissante | |
HK1210049A1 (en) | Combination therapies for treating cancer | |
GB201218996D0 (en) | Improved panel | |
EP2914254A4 (fr) | Polythérapies | |
EP2911673A4 (fr) | Combinaison | |
GB201217439D0 (en) | Combination therapy | |
EP2882792A4 (fr) | Polycarbonates | |
GB201320563D0 (en) | Anti-infection unit | |
GB2504567B (en) | Anti-Relatch Mechanism | |
HK1210426A1 (en) | Combination therapy | |
EP2934500A4 (fr) | Polythérapie pour le traitement du cancer | |
HU4381U (en) | Arrangement for divided enery-production | |
EP2914267A4 (fr) | Traitement contre la constipation | |
GB2500605B (en) | Lock mechanism | |
HK1212895A1 (zh) | 用於免疫調節的沙奎那韋- | |
EP2925728A4 (fr) | Combinaison | |
GB201304493D0 (en) | Not published |